Gijsbert Veerman

2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Jan B. Vermorken et al. · Biochemical Pharmacology · 1993 · 251 citations

Nucleic Acid Chemistry, Natural Sciences, Nucleic Acid Biochemistry +8

<i>In vivo</i> Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant

Andries M. Bergman, Paul P. Eijk, Veronique W.T. Ruiz van Haperen et al. · Cancer Research · 2005 · 180 citations · Full text

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, S. Eriksson et al. · PubMed · 1994 · 168 citations

Chemoprevention Strategy, Gynecology, Cancer Biology +23

Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Epie Boven et al. · Biochemical Pharmacology · 1994 · 125 citations

Oncology, Schedule Dependence, Biochemistry +9

Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors

Gijsbert Veerman, Veronique W.T. Ruiz van Haperen, Jan B. Vermorken et al. · Cancer Chemotherapy and Pharmacology · 1996 · 95 citations

Tumor Biology, Oncology, Antitumor Activity +10